Asth­ma pa­tients are un­fa­mil­iar with bi­o­log­ic brands, but open to try — Phree­sia sur­vey

Peo­ple liv­ing with asth­ma are open to try­ing new bi­o­log­ic treat­ments now on the mar­ket — they just haven’t heard of them. On­ly 5% have heard of Dupix­ent, Sanofi and Re­gen­eron’s mul­ti-in­di­ca­tion asth­ma and eczema block­buster, a new sur­vey from Phree­sia re­port­ed.

Con­sid­er­ing the fact that Dupix­ent spent more than half a bil­lion on ad­ver­tis­ing in 2021 — $524 mil­lion to be ex­act and the high­est me­dia spend­ing by any phar­ma brand in 2021 — that would seem to be a fair­ly low aware­ness num­ber.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.